Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
December 6, 2023
Chemistry, Manufacturing, and Controls (CMC) is a critical component of drug product development. As a Senior...
Read article
May 5, 2020
Webinar: A Clinician’s Perspective on Cancer Drugs Development
Cytel's team of oncology trial design and advanced analytics experts are hosting a series of complimentary webinars...
Read article
April 23, 2020
A Clinician’s Perspective on Cancer Drugs Development
Cytel is hosting a webinar, “A Clinician’s Perspective on Cancer Drugs Development”, on April 28, 2020. Our speaker,...
Read article
October 19, 2015
3 Statistical Challenges for Pooling Phase 1 Data
It is often necessary to pool safety data from late phase studies, in preparation for regulatory submission. Some of...
Read article
December 4, 2014
Operationally Seamless & Inferentially Seamless Adaptive Designs
Fulyzaq® from Napo/Salix was the first drug ever to be approved using an adaptive two-stage "seamless" clinical trial...
Read article
November 4, 2014
New Exploratory Trial Method Translates into Better Financial Strategy
A key stage of exploratory drug development is implementing a proof-of-concept study to demonstrate the safety of a...
Read article
April 24, 2014
New JAMA Study Confirms Importance of Trial Design for FDA Approval
Here at Cytel we firmly believe that if you don’t get the design of a clinical program right, then nothing else...
Read article